UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

C/EBPB-dependent adaptation to palmitic acid promotes tumor formation in hormone receptor negative breast cancer

Nature communications, 2022-01, Vol.13 (1), p.69-69, Article 69

2022

Volltextzugriff (PDF)

Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation

Journal of investigative dermatology, 2015-07, Vol.135 (7), p.1820-1828

2015

Volltextzugriff (PDF)

Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy

BMC cancer, 2012-01, Vol.12 (1), p.39-39, Article 39

2012

Volltextzugriff (PDF)

Assessing Novel Therapies Based on Late-Stage Efficacy: A Dangerous Concept?

Trends in Cancer, 2021-03, Vol.7 (3), p.181-185

Lønning, Per E

2021

Volltextzugriff (PDF)

Repeated Observation of Breast Tumor Subtypes in Independent Gene Expression Data Sets

Proceedings of the National Academy of Sciences - PNAS, 2003-07, Vol.100 (14), p.8418-8423

2003

Volltextzugriff (PDF)

Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC

Cancer & metabolism, 2019-06, Vol.7 (1), p.6-6, Article 6

2019

Volltextzugriff (PDF)

Predicting long-term survival and treatment response in breast cancer patients receiving neoadjuvant chemotherapy by MR metabolic profiling

NMR in biomedicine, 2012-02, Vol.25 (2), p.369-378

2012

Volltextzugriff (PDF)

MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk

Oncotarget, 2011-03, Vol.2 (3), p.251-258

2011

Volltextzugriff (PDF)

Poor-prognosis estrogen receptor- positive disease: present and future clinical solutions

Therapeutic Advances in Medical Oncology, 2012-05, Vol.4 (3), p.127-137

Lønning, Per E.

2012

Volltextzugriff (PDF)

Effects of the MDM2 promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk

Transcription, 2011-09, Vol.2 (5), p.207-210

2011

Volltextzugriff (PDF)

Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines

Oncotarget, 2017-06, Vol.8 (25), p.41227-41241

2017

Volltextzugriff (PDF)

NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients

Breast cancer research : BCR, 2018-10, Vol.20 (1), p.120-120, Article 120

2018

Volltextzugriff (PDF)

Comment on "Towards a personalized approach to aromatase inhibitor therapy: a digital microfluidic platform for rapid analysis of estradiol in core-needle-biopsies" by S. Abdulwahab, A. H. C. Ng, M. D. Chamberlain, H. Ahmado, L.-A. Behan, H. Gomaa, R. F. Casper and A. R. Wheeler, Lab Chip, 2017, 17, 1594

Lab on a chip, 2017-09, Vol.17 (18), p.3186-3187

Lønning, Per E

2017

Volltextzugriff (PDF)

Chemosensitivity and p53; new tricks by an old dog

Breast cancer research : BCR, 2012-11, Vol.14 (6), p.325-325, Article 325

2012

Volltextzugriff (PDF)

Impact of aromatase inhibitors on bone health in breast cancer patients

Journal of steroid biochemistry and molecular biology, 2010-02, Vol.118 (4), p.294-299

2010

Volltextzugriff (PDF)

MDM2 promoter SNP344T>A (rs1196333) status does not affect cancer risk

PloS one, 2012-04, Vol.7 (4), p.e36263-e36263

2012

Volltextzugriff (PDF)

Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin

Biochimica et biophysica acta, 2013-03, Vol.1830 (3), p.2790-2797

2013

Volltextzugriff (PDF)

Impact of the APOBEC3A/B deletion polymorphism on risk of ovarian cancer

Scientific reports, 2021-12, Vol.11 (1), p.23463-23463, Article 23463

2021

Volltextzugriff (PDF)

The Functional Roles of the MDM2 Splice Variants P2-MDM2-10 and MDM2-∆5 in Breast Cancer Cells

Translational oncology, 2017-10, Vol.10 (5), p.806-817

2017

Volltextzugriff (PDF)

Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma

PloS one, 2013-08, Vol.8 (8), p.e72692-e72692

2013

Volltextzugriff (PDF)

Alterations in the p53 Pathway and p16INK4a Expression Predict Overall Survival in Metastatic Melanoma Patients Treated with Dacarbazine

Journal of investigative dermatology, 2010-10, Vol.130 (10), p.2514-2516

2010

Volltextzugriff (PDF)

Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer

Breast cancer research : BCR, 2012-03, Vol.14 (2), p.R47-R47, Article R47

2012

Volltextzugriff (PDF)

Prenatal BRCA1 epimutations contribute significantly to triple-negative breast cancer development

Genome medicine, 2023-12, Vol.15 (1), p.104-15, Article 104

2023

Volltextzugriff (PDF)

Aromatase inhibitors: Assessment of biochemical efficacy measured by total body aromatase inhibition and tissue estrogen suppression

Journal of steroid biochemistry and molecular biology, 2008-02, Vol.108 (3), p.196-202

2008

Volltextzugriff (PDF)

1 – 25 von 137

Suche als RSS-Feed

Aktive Filter

KollektionJournals@Ovid

Zeitschrift / SerieCancer Chemotherapy And Pharmacology

SpracheJapanisch

SpracheNorwegisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(130)
Mit Volltextzugriff
(133)

Publikationsform

Artikel
(136)
Buchkapitel
(1)

Sprache

Englisch
(137)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

C/EBPB-dependent adaptation to palmitic acid promotes tumor formation in hormone receptor negative breast cancer

Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation

Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy

Assessing Novel Therapies Based on Late-Stage Efficacy: A Dangerous Concept?

Repeated Observation of Breast Tumor Subtypes in Independent Gene Expression Data Sets

Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC

Predicting long-term survival and treatment response in breast cancer patients receiving neoadjuvant chemotherapy by MR metabolic profiling

Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial

MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk

Poor-prognosis estrogen receptor- positive disease: present and future clinical solutions

Effects of the MDM2 promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk

Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines

NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients

Chemosensitivity and p53; new tricks by an old dog

Impact of aromatase inhibitors on bone health in breast cancer patients

MDM2 promoter SNP344T>A (rs1196333) status does not affect cancer risk

Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin

Impact of the APOBEC3A/B deletion polymorphism on risk of ovarian cancer

The Functional Roles of the MDM2 Splice Variants P2-MDM2-10 and MDM2-∆5 in Breast Cancer Cells

Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma

Alterations in the p53 Pathway and p16INK4a Expression Predict Overall Survival in Metastatic Melanoma Patients Treated with Dacarbazine

Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer

Prenatal BRCA1 epimutations contribute significantly to triple-negative breast cancer development

Aromatase inhibitors: Assessment of biochemical efficacy measured by total body aromatase inhibition and tissue estrogen suppression

Aktive Filter

Suchergebnisse filtern